仙乐健康(300791) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥951,504,195.36, representing a 35.51% increase compared to ¥702,158,705.58 in the same period last year[4] - Net profit attributable to shareholders was ¥63,029,722.56, a significant increase of 114.39% from ¥29,399,867.21 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥64,930,448.59, up 155.07% from ¥25,455,628.46 in the previous year[4] - The basic earnings per share increased to ¥0.3472, reflecting a growth of 113.14% compared to ¥0.1629 in the same period last year[4] - The net profit for Q1 2024 was CNY 53,871,136.53, a significant increase from CNY 18,758,317.18 in Q1 2023, representing a growth of approximately 187.5%[27] - The operating profit for Q1 2024 was CNY 72,914,248.06, up from CNY 24,965,230.25 in Q1 2023, reflecting a growth of approximately 192.3%[27] - The company reported a total comprehensive income of CNY 27,178,195.12 for Q1 2024, compared to a loss of CNY 110,875,780.68 in Q1 2023[27] Cash Flow and Expenses - The company reported a net cash flow from operating activities of -¥72,301,258.02, a decline of 290.87% from ¥37,879,957.19 in the previous year, primarily due to increased procurement expenses[13] - The company's cash and cash equivalents decreased to RMB 413,703,447.28 from RMB 534,486,633.88 at the beginning of the period, a decline of 22.6%[24] - The cash flow from operating activities showed a net outflow of CNY 72,301,258.02, contrasting with a net inflow of CNY 37,879,957.19 in the same period last year[30] - The company incurred a total investment cash outflow of CNY 180,355,134.16 in Q1 2024, compared to CNY 728,378,578.08 in the previous year[30] - The net cash flow from financing activities was CNY 28,352,482.68, a recovery from a net outflow of CNY 261,283,175.80 in Q1 2023[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,127,433,664.78, a slight decrease of 1.31% from ¥5,195,727,810.16 at the end of the previous year[4] - The total liabilities decreased to RMB 2,549,367,451.40 from RMB 2,629,559,140.26, reflecting a reduction of 3.0%[25] - Accounts receivable increased to RMB 623,889,293.07 from RMB 612,751,607.59, showing a slight increase of 1.9%[24] - Inventory rose to RMB 500,437,189.57 from RMB 481,058,631.43, marking an increase of 4.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,251[15] - Guangdong Guanghui Investment Co., Ltd. holds 42.83% of the shares, amounting to 77,760,000 shares[15] - Lin Peiqing and Chen Qiong, as actual controllers, hold a combined total of 16,588,800 shares, representing 9.14% of the company's equity[16] - The top ten shareholders do not participate in margin trading or securities lending[17] - The total number of restricted shares at the end of the period is 31,605,473, with 10,851 shares released during the period[19] - The company has no preferred shareholders or changes in preferred shareholder structure[17] - The company maintains a stable shareholder structure with no significant changes reported[17] - The report indicates that Lin Peiqing holds shares as a trustee, with economic benefits directed to the beneficiaries of the trust[16] Research and Development - Research and development expenses rose to ¥30,794,385.11, marking a 36.99% increase from ¥22,478,475.33 in the previous year, indicating a focus on innovation[11] Marketing and Sales - Sales expenses increased by 39.75% to ¥73,086,246.12, attributed to enhanced marketing activities and sales team upgrades[11] Taxation - The company experienced a 150.64% increase in income tax expenses, amounting to ¥15,453,196.98, driven by business growth[11] - The company reported a tax expense of CNY 15,453,196.98 for Q1 2024, compared to CNY 6,165,404.20 in the same period last year, indicating an increase of approximately 150.0%[27] Investments and Joint Ventures - The company established a joint investment fund with Shanghai Hongzhang, targeting a total subscription amount of up to RMB 204 million, with an initial subscription of RMB 130 million[20] - The company completed its share repurchase plan, buying back 1,285,600 shares, representing 0.71% of the total share capital, for a total amount of RMB 39,899,697.35[21] Market and Product Development - The company has not disclosed any new product or technology developments in the current report[19] - There are no indications of market expansion or mergers and acquisitions in the current reporting period[19]